PT3604294T - Compostos e composições para modular atividades da cinase do mutante de egfr - Google Patents
Compostos e composições para modular atividades da cinase do mutante de egfrInfo
- Publication number
- PT3604294T PT3604294T PT191967132T PT19196713T PT3604294T PT 3604294 T PT3604294 T PT 3604294T PT 191967132 T PT191967132 T PT 191967132T PT 19196713 T PT19196713 T PT 19196713T PT 3604294 T PT3604294 T PT 3604294T
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- compounds
- kinase activities
- egfr mutant
- mutant kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462063394P | 2014-10-13 | 2014-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3604294T true PT3604294T (pt) | 2021-07-29 |
Family
ID=55654993
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT158503144T PT3207035T (pt) | 2014-10-13 | 2015-10-13 | Compostos e composições para modular actividades da cinase do mutante de egfr |
PT191967132T PT3604294T (pt) | 2014-10-13 | 2015-10-13 | Compostos e composições para modular atividades da cinase do mutante de egfr |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT158503144T PT3207035T (pt) | 2014-10-13 | 2015-10-13 | Compostos e composições para modular actividades da cinase do mutante de egfr |
Country Status (25)
Country | Link |
---|---|
US (1) | US9593098B2 (pt) |
EP (3) | EP3604294B1 (pt) |
JP (3) | JP6524221B2 (pt) |
KR (4) | KR102208775B1 (pt) |
CN (2) | CN106795144B (pt) |
AU (1) | AU2015331166B2 (pt) |
BR (1) | BR112017007769B1 (pt) |
CA (1) | CA2962914C (pt) |
CY (2) | CY1122737T1 (pt) |
DK (2) | DK3207035T3 (pt) |
ES (2) | ES2879474T3 (pt) |
HR (2) | HRP20200201T1 (pt) |
HU (2) | HUE048006T2 (pt) |
LT (2) | LT3604294T (pt) |
MX (3) | MX2017003181A (pt) |
NZ (1) | NZ730012A (pt) |
PH (1) | PH12017500488A1 (pt) |
PL (2) | PL3207035T3 (pt) |
PT (2) | PT3207035T (pt) |
RS (2) | RS61865B1 (pt) |
RU (2) | RU2727700C2 (pt) |
SG (1) | SG11201701960XA (pt) |
SI (2) | SI3604294T1 (pt) |
TW (2) | TWI664173B (pt) |
WO (1) | WO2016060443A2 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017003181A (es) * | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
MX2018013413A (es) | 2016-05-26 | 2019-06-06 | Zeno Royalties & Milestones Llc | Compuestos inhibidores de egfr. |
KR102030886B1 (ko) * | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
BR112019025836A2 (pt) * | 2017-06-13 | 2020-07-07 | Beijing Adamadle Biotechnology Limited Liability Company | composto de aminopirimidina, método de preparação do mesmo e uso do mesmo |
MA49703A (fr) * | 2017-07-28 | 2021-04-21 | Yuhan Corp | Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci |
RS64654B1 (sr) * | 2017-07-28 | 2023-10-31 | Yuhan Corp | Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom |
SG11201913556SA (en) * | 2017-07-28 | 2020-02-27 | Yuhan Corp | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same |
WO2019042187A1 (zh) | 2017-08-30 | 2019-03-07 | 深圳市塔吉瑞生物医药有限公司 | 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途 |
CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
CN108047207A (zh) * | 2018-01-30 | 2018-05-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺氘代物及应用 |
KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
EP3885346A4 (en) * | 2018-12-21 | 2022-01-12 | Shenzhen TargetRx, Inc. | AMINOPYRIMIDINE COMPOUND USED TO INHIBIT PROTEIN KINASE ACTIVITY |
JOP20210233A1 (ar) | 2019-02-26 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met. |
SG11202110376XA (en) * | 2019-03-19 | 2021-10-28 | Voronoi Inc | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component |
MA55508A (fr) | 2019-03-29 | 2022-02-09 | Astrazeneca Ab | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules |
CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
US11850248B2 (en) * | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
JOP20210304A1 (ar) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث |
CN110128354A (zh) * | 2019-06-20 | 2019-08-16 | 大连大学 | 一种5-氟-2-甲磺酰基-4-氨基嘧啶的制备方法 |
KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
MX2022008874A (es) | 2020-01-20 | 2022-08-11 | Astrazeneca Ab | Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer. |
TW202207940A (zh) | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
KR20210152312A (ko) * | 2020-06-08 | 2021-12-15 | 주식회사 종근당 | 카나비노이드 수용체 (cb1 수용체) 길항제로서의 4-(4,5-디하이드로-1h-피라졸-1-닐)피리미딘 화합물 및 이를 포함하는 약제학적 조성물 |
AU2021339962A1 (en) | 2020-09-14 | 2023-05-25 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
WO2022131741A1 (ko) * | 2020-12-14 | 2022-06-23 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
CN117255792A (zh) * | 2021-05-07 | 2023-12-19 | 沃若诺伊公司 | 杂芳基衍生物、其制备方法以及包括其作为活性成分的药物组合物 |
KR102607051B1 (ko) * | 2021-05-17 | 2023-11-30 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
EP4349835A1 (en) | 2021-06-01 | 2024-04-10 | Hangzhou Solipharma Co., Ltd. | Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof |
KR20230054567A (ko) | 2021-10-15 | 2023-04-25 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
TW202342057A (zh) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用egfr/met雙特異性抗體治療之患者的輸注相關反應之方法 |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1429222A (zh) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
MXPA05005547A (es) * | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
JP4428565B2 (ja) | 2004-10-05 | 2010-03-10 | 東京エレクトロン株式会社 | 処理液塗布装置 |
US20070072894A1 (en) | 2005-03-24 | 2007-03-29 | Kempf J V | Synthesis of pyrroloquinoline quinone (PQQ) |
JP5007029B2 (ja) | 2005-07-13 | 2012-08-22 | Ntn株式会社 | グリース組成物および該グリース封入転がり軸受 |
AU2006283935A1 (en) | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | Fused pyrazole as p38 MAP kinase inhibitors |
JP2007117465A (ja) | 2005-10-28 | 2007-05-17 | Sharp Corp | 集塵器およびそれを備えた電気掃除機 |
WO2007111471A1 (en) | 2006-03-29 | 2007-10-04 | Ktfreetel Co., Ltd. | Digital device and method for providing additional service by using the same |
JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
US8629132B2 (en) * | 2009-11-13 | 2014-01-14 | Genosco | Kinase inhibitors |
AU2012221927B2 (en) * | 2011-02-25 | 2016-04-28 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
PL3686194T3 (pl) * | 2011-07-27 | 2022-01-17 | Astrazeneca Ab | Związki 2-(2,4,5-podstawione-anilino)pirymidynowe |
PL2804861T3 (pl) | 2012-01-20 | 2018-08-31 | Genosco | Podstawione związki pirymidyny i ich zastosowanie jako inhibitory SYK |
WO2014040555A1 (zh) * | 2012-09-12 | 2014-03-20 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
ES2792979T3 (es) * | 2013-08-22 | 2020-11-12 | Jubilant Biosys Ltd | Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos |
WO2015188777A1 (en) * | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
MX2017003181A (es) * | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
-
2015
- 2015-10-13 MX MX2017003181A patent/MX2017003181A/es active IP Right Grant
- 2015-10-13 LT LTEP19196713.2T patent/LT3604294T/lt unknown
- 2015-10-13 LT LTEP15850314.4T patent/LT3207035T/lt unknown
- 2015-10-13 SI SI201531611T patent/SI3604294T1/sl unknown
- 2015-10-13 EP EP19196713.2A patent/EP3604294B1/en active Active
- 2015-10-13 RU RU2017116598A patent/RU2727700C2/ru active
- 2015-10-13 JP JP2017519685A patent/JP6524221B2/ja active Active
- 2015-10-13 US US14/881,930 patent/US9593098B2/en active Active
- 2015-10-13 EP EP15850314.4A patent/EP3207035B1/en active Active
- 2015-10-13 KR KR1020207002949A patent/KR102208775B1/ko active IP Right Grant
- 2015-10-13 AU AU2015331166A patent/AU2015331166B2/en active Active
- 2015-10-13 SG SG11201701960XA patent/SG11201701960XA/en unknown
- 2015-10-13 ES ES19196713T patent/ES2879474T3/es active Active
- 2015-10-13 RS RS20210608A patent/RS61865B1/sr unknown
- 2015-10-13 BR BR112017007769-8A patent/BR112017007769B1/pt active IP Right Grant
- 2015-10-13 PL PL15850314T patent/PL3207035T3/pl unknown
- 2015-10-13 CA CA2962914A patent/CA2962914C/en active Active
- 2015-10-13 DK DK15850314.4T patent/DK3207035T3/da active
- 2015-10-13 NZ NZ730012A patent/NZ730012A/en unknown
- 2015-10-13 PL PL19196713T patent/PL3604294T3/pl unknown
- 2015-10-13 HU HUE15850314A patent/HUE048006T2/hu unknown
- 2015-10-13 TW TW104133539A patent/TWI664173B/zh active
- 2015-10-13 CN CN201580055717.9A patent/CN106795144B/zh active Active
- 2015-10-13 KR KR1020217002019A patent/KR102487451B1/ko active IP Right Grant
- 2015-10-13 KR KR1020237000623A patent/KR102662358B1/ko active IP Right Grant
- 2015-10-13 WO PCT/KR2015/010784 patent/WO2016060443A2/en active Application Filing
- 2015-10-13 CN CN202010422259.0A patent/CN111686110B/zh active Active
- 2015-10-13 HU HUE19196713A patent/HUE054848T2/hu unknown
- 2015-10-13 MX MX2020002168A patent/MX2020002168A/es unknown
- 2015-10-13 DK DK19196713.2T patent/DK3604294T3/da active
- 2015-10-13 PT PT158503144T patent/PT3207035T/pt unknown
- 2015-10-13 TW TW108118264A patent/TWI730331B/zh active
- 2015-10-13 KR KR1020177012969A patent/KR102073854B1/ko active Protection Beyond IP Right Term
- 2015-10-13 ES ES15850314T patent/ES2770058T3/es active Active
- 2015-10-13 PT PT191967132T patent/PT3604294T/pt unknown
- 2015-10-13 EP EP21171619.6A patent/EP3929190A1/en active Pending
- 2015-10-13 SI SI201531055T patent/SI3207035T1/sl unknown
- 2015-10-13 RU RU2020123547A patent/RU2020123547A/ru unknown
- 2015-10-13 RS RS20200101A patent/RS59900B1/sr unknown
-
2017
- 2017-03-10 MX MX2021010761A patent/MX2021010761A/es unknown
- 2017-03-14 PH PH12017500488A patent/PH12017500488A1/en unknown
-
2019
- 2019-04-26 JP JP2019085608A patent/JP6754864B2/ja active Active
-
2020
- 2020-02-07 HR HRP20200201TT patent/HRP20200201T1/hr unknown
- 2020-02-17 CY CY20201100143T patent/CY1122737T1/el unknown
- 2020-08-24 JP JP2020141205A patent/JP2020196740A/ja not_active Withdrawn
-
2021
- 2021-06-14 HR HRP20210949TT patent/HRP20210949T1/hr unknown
- 2021-07-26 CY CY20211100670T patent/CY1124359T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200201T1 (hr) | Spojevi i sastavi za moduliranje aktivnosti mutantne egfr kinaze | |
IL273058A (en) | Compositions and methods for modulation of PKK expression | |
HK1258811A1 (zh) | 用於調節cftr 的化合物、組合物和方法 | |
IL286669A (en) | Compounds and methods for modulating tmprss6 expression | |
HK1258275A1 (zh) | 用於調節血管緊張素原表達的化合物和方法 | |
IL246879B (en) | Preparations of Epilimod and methods of using them | |
ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
HRP20180920T1 (hr) | Mješoviti travnjak | |
EP3102571A4 (en) | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | |
PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
IL252191B (en) | Compositions and methods for modulating at2r activity | |
SG10202003691PA (en) | Composition for modulating irak1 | |
GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |